These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 27747241)

  • 1. Role of Cilostazol Therapy in Hemodialysis Patients with Asymptomatic Peripheral Arterial Disease: A Retrospective Cohort Study.
    Lim PS; Jeng Y; Wu MY; Pai MA; Wu TK; Chen CH
    Biomed Res Int; 2016; 2016():8236903. PubMed ID: 27747241
    [No Abstract]   [Full Text] [Related]  

  • 2. Treatment with cilostazol improves clinical outcome after endovascular therapy in hemodialysis patients with peripheral artery disease.
    Ishii H; Aoyama T; Takahashi H; Kumada Y; Kamoi D; Sakakibara T; Umemoto N; Suzuki S; Tanaka A; Ito Y; Murohara T
    J Cardiol; 2016 Feb; 67(2):199-204. PubMed ID: 26074442
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cilostazol improves long-term patency after percutaneous transluminal angioplasty in hemodialysis patients with peripheral artery disease.
    Ishii H; Kumada Y; Toriyama T; Aoyama T; Takahashi H; Yamada S; Yasuda Y; Yuzawa Y; Maruyama S; Matsuo S; Matsubara T; Murohara T
    Clin J Am Soc Nephrol; 2008 Jul; 3(4):1034-40. PubMed ID: 18322041
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Restenosis after stent implantation for superficial femoral artery disease in patients treated with cilostazol.
    Soga Y; Iida O; Hirano K; Suzuki K; Yokoi H; Nobuyoshi M
    Catheter Cardiovasc Interv; 2012 Mar; 79(4):541-8. PubMed ID: 21805619
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The efficacy and safety of cilostazol in ischemic stroke patients with peripheral arterial disease (SPAD): protocol of a randomized, double-blind, placebo-controlled multicenter trial.
    Jeng JS; Sun Y; Lee JT; Lin RT; Chen CH; Po HL; Lin HJ; Liu CH; Sun MH; Sun MC; Chern CM; Lien LM; Chiu HC; Hu HH; Chiou HY; Chen ST; Ma H; Hsu CY;
    Int J Stroke; 2015 Jan; 10(1):123-7. PubMed ID: 25394855
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cilostazol for primary prevention of stroke in peripheral artery disease: a population-based longitudinal study in Taiwan.
    Lee WH; Chu CY; Hsu PC; Su HM; Lin TH; Voon WC; Lai WT; Sheu SH
    Thromb Res; 2013 Aug; 132(2):190-5. PubMed ID: 23433530
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Randomized pilot trial between prostaglandin I2 analog and anti-platelet drugs on peripheral arterial disease in hemodialysis patients.
    Ohtake T; Sato M; Nakazawa R; Kondoh M; Miyaji T; Moriya H; Hidaka S; Kobayashi S
    Ther Apher Dial; 2014 Feb; 18(1):1-8. PubMed ID: 24499078
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of the antiplatelet agent cilostazol on endovascular inflammatory biochemical parameters and the clinical symptoms of peripheral artery disease and restless legs syndrome in hemodialysis patients.
    Shiohira S; Yoshida T; Sugiura H; Yoshida S; Mitobe M; Shimada K; Ohba T; Tsuchiya K; Kabaya T; Nitta K
    Clin Exp Nephrol; 2011 Dec; 15(6):893-9. PubMed ID: 21773691
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of cilostazol on arterial wound healing: a retrospective analysis.
    Resnick KA; Gordon IL
    Ann Vasc Surg; 2014 Aug; 28(6):1513-21. PubMed ID: 24561209
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cilostazol does not improve peripheral arterial disease-linked oxidative stress.
    Bernal-Lopez MR; Peña D; Gomez-Martin P; Tinahones FJ; Gomez-Huelgas R
    Cardiovasc Ther; 2015 Feb; 33(1):15-9. PubMed ID: 25393963
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-Term Effectiveness of Cilostazol in Patients with Hemodialysis with Peripheral Artery Disease.
    Wu CK; Lin CH; Yar N; Kao ZK; Yang YB; Chen YY
    J Atheroscler Thromb; 2023 Aug; 30(8):943-955. PubMed ID: 36216573
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Practice-based evidence: profiling the safety of cilostazol by text-mining of clinical notes.
    Leeper NJ; Bauer-Mehren A; Iyer SV; Lependu P; Olson C; Shah NH
    PLoS One; 2013; 8(5):e63499. PubMed ID: 23717437
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Three-year cardiovascular events and disease progress in patients with peripheral arterial disease: results from the Japan Medication Therapy for Peripheral Arterial Disease (J-METHOD).
    Shigematsu H; Nishibe T; Obitsu Y; Matsuzaki K; Ishida A; Miyata T; Shindo S; Hida K; Ohta T; Ando M; Kawasaki T; Yasugi T; Matsumoto T
    Int Angiol; 2010 Apr; 29(2 Suppl):2-13. PubMed ID: 20357743
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ankle brachial pressure index but not brachial-ankle pulse wave velocity is a strong predictor of systemic atherosclerotic morbidity and mortality in patients on maintenance hemodialysis.
    Tanaka M; Ishii H; Aoyama T; Takahashi H; Toriyama T; Kasuga H; Takeshita K; Yoshikawa D; Amano T; Murohara T
    Atherosclerosis; 2011 Dec; 219(2):643-7. PubMed ID: 22018643
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multicenter randomized trial evaluating the efficacy of cilostazol on ischemic vascular complications after drug-eluting stent implantation for coronary heart disease: results of the CILON-T (influence of CILostazol-based triple antiplatelet therapy ON ischemic complication after drug-eluting stenT implantation) trial.
    Suh JW; Lee SP; Park KW; Lee HY; Kang HJ; Koo BK; Cho YS; Youn TJ; Chae IH; Choi DJ; Rha SW; Bae JH; Kwon TG; Bae JW; Cho MC; Kim HS
    J Am Coll Cardiol; 2011 Jan; 57(3):280-9. PubMed ID: 21232664
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cilostazol and outcome in outpatients with peripheral artery disease.
    Perez P; Esteban C; Sauquillo JC; Yeste M; Manzano L; Mujal A; Jiménez Caballero PE; Aguilar E; Sánchez Muñoz-Torrero JF; Monreal M;
    Thromb Res; 2014 Aug; 134(2):331-5. PubMed ID: 24951338
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cilostazol reduces angiographic restenosis after endovascular therapy for femoropopliteal lesions in the Sufficient Treatment of Peripheral Intervention by Cilostazol study.
    Iida O; Yokoi H; Soga Y; Inoue N; Suzuki K; Yokoi Y; Kawasaki D; Zen K; Urasawa K; Shintani Y; Miyamoto A; Hirano K; Miyashita Y; Tsuchiya T; Shinozaki N; Nakamura M; Isshiki T; Hamasaki T; Nanto S;
    Circulation; 2013 Jun; 127(23):2307-15. PubMed ID: 23652861
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sarpogrelate hydrochloride, a selective 5-HT(2A) receptor antagonist, improves skin perfusion pressure of the lower extremities in hemodialysis patients with peripheral arterial disease.
    Hidaka S; Kobayashi S; Iwagami M; Isshiki R; Tsutsumi D; Mochida Y; Ishioka K; Oka M; Maesato K; Moriya H; Ohtake T
    Ren Fail; 2013; 35(1):43-8. PubMed ID: 23110683
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cilostazol may prevent cardioembolic stroke in patients undergoing antiplatelet therapy.
    Horie N; Kaminogo M; Izumo T; Hayashi K; Tsujino A; Nagata I
    Neurol Res; 2015 Jul; 37(7):619-23. PubMed ID: 25798683
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Benefit of cilostazol in patients with high risk of bleeding: subanalysis of cilostazol stroke prevention study 2.
    Uchiyama S; Shinohara Y; Katayama Y; Yamaguchi T; Handa S; Matsuoka K; Ohashi Y; Tanahashi N; Yamamoto H; Genka C; Kitagawa Y; Kusuoka H; Nishimaru K; Tsushima M; Koretsune Y; Sawada T; Hamada C
    Cerebrovasc Dis; 2014; 37(4):296-303. PubMed ID: 24820203
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.